Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

SK Bioscience Co. Ltd. won €50 million (₩75.5 billion, US$52.03 million) up front from Sanofi SA to expand an earlier ...

Wave Life Sciences Ltd. has submitted a clinical trial application (CTA) for WVE-007, an investigational GalNAc-conjugated ...

Hervolution Therapeutics ApS (formerly Inprother Aps) has announced a $11.7 million series A financing to support its work ...

AI-powered drug R&D platform firm Oncocross Co. Ltd. is leading the procession of year-end Korea biotech IPOs this week, ...

As if the uncertainties surrounding an incoming administration weren’t enough, a landmark U.S. Supreme Court decision and a potential new avenue of liability for drug and device manufacturers could ...

Radiopharm Theranostics Ltd. has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I therapeutic study of 177Lu-labelled RAD-202 ...

Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton ...

Deciphera Pharmaceuticals LLC has divulged eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.

Solve Therapeutics Inc. has identified antibody-drug conjugates comprising an UC-961 antibody or a tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)-targeting antibody covalently linked to ...